E-mail a Wiley Online Library Link

K.A. Papp, R.G. Langley, B. Sigurgeirsson, M. Abe, D.R. Baker, P. Konno, S. Haemmerle, H.J. Thurston, C. Papavassilis and H.B. Richards Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study British Journal of Dermatology 168

Version of Record online: 18 JAN 2013 | DOI: 10.1111/bjd.12110

What’s already known about this topic?

  • Conventional systemic therapies for plaque psoriasis have not fully met patient needs; biologics, although effective and generally well tolerated, have a still-developing long-term safety profile.
  • Monoclonal antibodies against interleukin (IL)-17A have shown early promise.

What does this study add?

  • In this study, the investigational anti-IL-17 monoclonal secukinumab (3 × 150 mg, 3 × 75 mg subcutaneously) produced significantly higher rates of 75% improvement from baseline in Psoriasis Area and Severity Index score vs. placebo, and was well tolerated in moderate-to-severe plaque psoriasis.
  • Secukinumab may offer new therapeutic options in plaque psoriasis.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field